Peg-IFN-alfa2a/Ribavirin combination therapy for chronic hepatitis C with serogroup1 and high viral load: analysis of IL28B gene and efficacy of vitamin D combinatio
Not Applicable
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000008197
- Lead Sponsor
- Kanazawa university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
contraindication of Peg-IFN/Ribavirin therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method